摘要
目的探究左卡尼丁联合重组人促红素在血液透析患者治疗中的应用价值。方法选取2021年2月~2023年2月我院收治的80例血液透析患者,根据计算机法将其分为对照组和观察组,每组各40例。对照组使用重组人促红素治疗,观察组使用重组人促红素+左卡尼丁治疗。对比两组治疗前后血清炎症因子[白细胞介素-6(interleukin-6,IL-6)、C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)、肿瘤坏死因子α(tumor necrosis factor-α,TNF-α)]、贫血相关指标[转铁蛋白受体(soluble transferrin receptor,sTfR)、铁蛋白(serum ferritin,SF)、转铁蛋白饱和度(transferrin saturation,TAST)、血红蛋白(hemoglobin,Hb)]以及不良反应。结果治疗前,两组IL-6、hs-CRP、TNF-α水平对比,差异不具有显著性(P>0.05);治疗后,两组IL-6、hs-CRP、TNF-α水平均有下降,观察组较对照组下降明显,差异具有显著性(P<0.05)。治疗前,两组s Tf R、SF、TAST、Hb水平对比,差异不具有显著性(P>0.05);治疗后,两组s Tf R水平下降,SF、TAST、Hb水平均有上升,观察组较对照组改善明显,差异具有显著性(P<0.05);两组不良反应发生率对比差异不具有显著性(P>0.05)。结论左卡尼丁与重组人促红素联合应用于血液透析患者的治疗中,能有效降低患者机体炎性反应,改善营养状态,不会增加不良反应,安全性能得到保证。
Objective:To explore the application value of levocarnitine combined with recombinant human erythropoietin in hemodialysis patients.Methods:A total of 80 hemodialysis patients treated in our hospital from February 2021 to February 2023 were selected,and were divided into the control group and the observation group,with 40 cases in each group.The control group was treated with recombinant human erythropoietin and the observation group was treated with recombinant human erythropoietin+levocarnitine according to the computer method.Serum inflammatory cytokines[interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)]and anemia related indicators[soluble transferrin receptor,(sTfR),serum ferritin(SF),transferrin saturation(TAST),hemoglobin(Hb)]and adverse reactions were compared.Results:Before treatment,there was no significant difference in the levels of IL-6,hs-CRP and TNF-αbetween the two groups(P>0.05).After treatment,the levels of IL-6,hs-CRP and TNF-αdecreased in both groups,which were significantly lower in the observation group than those in the control group(P<0.05);Before treatment,there was no significant difference in the levels of sTfR,SF,TAST and Hb between the two groups(P>0.05).After treatment,the levels of sTfR decreased while those of SF,TAST and Hb increased in both groups.The level in the observation group improved significantly compared with that in the control group,and the difference was significant(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Levocarnitine combined with recombinant human erythropoietin in hemodialysis patients can effectively reduce the inflammatory response,improve nutritional status without increasing adverse reactions,and ensure safety.
作者
黄开华
HUANG Kai-hua(People's Hospital of Wanzai County,Wanzai Jiangxi 336000,China)
出处
《透析与人工器官》
2024年第2期17-20,共4页
Chinese Journal of Dialysis and Artificial Organs
关键词
血液透析
左卡尼丁
重组人促红素
血清炎症因子
贫血相关指标
不良反应
hemodialysis
levocarnitine
recombinant human erythropoietin
serum inflammatory factors
anemia-related indicators
adverse reactions
